SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

43 2017 A - 2022 E Net Product Sales • Loss of Exclusivity (LOE) occurred on February 15, 2018. Branded volumes are expected to decrease into 2019 as a result of the launch of two generic entrants in 2H 2018 • Treximet ® AG: Currently a four - player market as of September 2018, up from two players earlier in the year, which will likely adversely affect volumes and pricing • Promotion by Sales Force ceased in January 2018 due to impending LOE and generic entrants ($ in millions) Note: Projections are subject to numerous assumptions and risks. $68 $22 $6 $6 $6 $7 $9 $4 $4 $3 $3 72% 74% 88% 88% 89% 89% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% $0 $20 $40 $60 $80 $100 $120 2017A 2018E 2019E 2020E 2021E 2022E Treximet Brand Sales Treximet AG Sales Gross Margin $ 31 $10 $10 $10 $ 10 Treximet ® Net Sales Forecast A A